Aehr Test Systems Insider Swings: Director Buys Low, Sells Near Peak as AI‑Processor Deal Fuels Mixed Signals

Insider Activity Highlights a Mixed Signal for Aehr Test Systems

The latest Rule 144 filing from Director Danesh Fariba shows a net buy of 8,000 shares at $2.25 per share on April 16, 2026, boosting his holding to 21,143 shares. In the same session he also sold 8,000 shares of common stock at $82.63 and liquidated a block of 8,000 non‑qualified options at no cash consideration. The timing—just after the company announced a record $41 million contract for AI‑processor package‑level burn‑in—suggests that Fariba is positioning himself for the expected upside while also hedging exposure to the current stock price.

Implications for Investors

Fariba’s dual activity underscores a cautious optimism. The buy at $2.25 is effectively a “long‑term play,” likely made before the public announcement. The sell at $82.63 aligns closely with the market price ($83.86) and may reflect a routine rebalancing rather than a loss signal. For investors, this pattern indicates that senior management remains confident in the AI‑processor push yet is mindful of short‑term volatility. If the new contract drives revenue growth, the stock could rally further, but the recent 19% weekly rise and 126% monthly gain already place the shares near a 52‑week high of $91.43, leaving limited room for immediate upside without a significant catalyst.

Fariba’s Historical Transaction Pattern

Fariba’s insider history shows a blend of aggressive buying and strategic selling. From October 2025 to April 2026 he purchased 7,000 shares in July 2025, sold 6,335 shares in October 2025, and has since been oscillating between large sales (up to 7,000 shares) and smaller purchases (7,000 shares in April 2026). His option sales (non‑qualified) are consistent, suggesting he uses options to generate cash without relinquishing equity exposure. Overall, Fariba has maintained a net long position, peaking at 25,643 shares in July 2025 and currently holding 21,143. This trend signals a belief in the company’s long‑term trajectory, tempered by periodic portfolio adjustments.

Company‑Wide Insider Activity Context

Other directors—Posedel Rhea, Howard Slayen, and Laura Oliphant—have collectively sold significant blocks in the past week, averaging 30,000 to 45,000 shares each. These sales are typical post‑announcement adjustments and do not appear to alter the ownership structure meaningfully. The broader insider landscape remains stable, with most executives maintaining holdings in the 100,000–200,000 share range, reinforcing confidence in Aehr’s strategic direction.

Takeaway for Stakeholders

For investors, the duality of Fariba’s transactions is a reminder that insider activity should be viewed in context. A sizable buy before a positive news cycle, followed by a near‑market sale, reflects both conviction and risk‑management. The company’s strong fundamentals—market cap of $2.3 billion, a negative P/E hinting at future earnings growth, and a recent AI‑processor contract—suggest a robust growth engine. However, the stock’s proximity to a 52‑week high warrants caution. Monitoring subsequent insider moves and the contract’s execution milestones will be key to assessing Aehr Test Systems’ trajectory.